Replimune Group, Inc. (REPL)
AI stock analysis · as of Aug 3, 2026
Loading microstructure…
Replimune is a pre-revenue clinical-stage oncolytic immunotherapy biotech whose entire near-term equity value hinges on FDA approval of RP1 (with nivolumab) in anti-PD-1-failed melanoma. After a second Complete Response Letter in April 2026 forced a restructuring and elimination of commercial staff, the company has resubmitted the BLA with a PDUFA date of August 2, 2026 and an AdCom expected in late July 2026. The core question: does a Class 1 resubmission plus strong 3-year IGNYTE OS data (32.9 mo median, 47.8% alive at 3 yr) overcome an FDA that has already rejected the drug twice and reversed prior guidance?
valuationNot valuable on multiples (no revenue, negative EV/EBITDA -2.5x, P/B 5.6x on eroding book); at ~$941M market cap the stock is effectively pricing a materially better-than-coin-flip probability of RP1 approval, which looks fair-to-full given two prior CRLs.
This analysis is from Aug 3, 2026. Want the latest on REPL, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Compelling clinical data: 3-year IGNYTE median OS of 32.9 months and 47.8% of all patients alive at 3 years in a population with few options; 83.5% of responders alive at 3 years supports durability narrative
- · IGNYTE-3 Phase 3 confirmatory trial is already running, providing a path to full approval regardless of the accelerated approval outcome and de-risking the long-term asset
- · Addressable market of ~10,400 eligible U.S. anti-PD-1-failed melanoma patients annually plus pipeline optionality in CSCC, MCC, BCC, angiosarcoma, and uveal melanoma (REVEAL Ph2/3 transition Q1 2027)
- · Extreme short interest (49.9% of float, 7.62 days to cover) sets up a violent squeeze if the July 2026 AdCom or August PDUFA breaks positive
- · Owned 63,000 sq ft Framingham cGMP manufacturing facility eliminates CMO dependency and supports commercial launch economics if approved
- · 1 upgrade vs 0 downgrades in the last 90 days and Buy consensus with analyst target mean of $12 (high $17) suggests sell-side still sees asymmetric upside into the catalyst
Bear case
- · FDA has rejected RP1 twice, including a second CRL on April 10, 2026 that reversed positions taken at the September 2025 Type A meeting — a pattern of regulatory reversal that is difficult to underwrite
- · Management explicitly warns that failure to obtain accelerated approval could force restructuring or wind-down of RP1 development; the April 2026 RIF already eliminated all in-house commercial staff
- · Going-concern profile: FY2026 net loss of $314M, FCF of -$285M, only $209M cash against $112M debt — the company is structurally reliant on dilutive ATM issuance and its term loan (Tranche 3 drawn Jan 2026)
- · Concentrated pipeline: RP3 paused, RP2 REVEAL Ph2/3 transition not until Q1 2027 — essentially no near-term value driver outside RP1
- · Debt/equity of 67x and P/B of 5.6x on a shrinking equity base signal balance-sheet fragility; ROE of -108% reflects rapid book erosion
- · Cantor Fitzgerald cut its target on April 13, 2026 following the second CRL, consistent with news of an ~85% target reduction from at least one analyst — sell-side reassessment is underway
Catalysts
- · FDA Advisory Committee meeting expected late July 2026 — historically the single biggest swing factor (news cites 127% aftermarket rally on prior favorable AdCom)
- · PDUFA action date August 2, 2026 for RP1 + nivolumab BLA resubmission — binary approve/reject outcome
- · Q1 FY2027 earnings on August 6, 2026 immediately post-PDUFA, likely to include forward guidance on commercial launch or restructuring path
- · Short squeeze potential: 49.9% short interest of float and 7.62 days to cover create violent upside mechanics on positive AdCom or approval
- · IGNYTE-3 interim/enrollment updates and REVEAL Phase 2/3 transition (Q1 2027) as longer-dated pipeline catalysts
Key risks
- · Third FDA rejection would likely trigger restructuring/wind-down language flagged in the 10-K and collapse equity value
- · Even with approval, rebuilding commercial infrastructure after the April 2026 RIF could delay launch and impair peak sales
- · Dilution risk via continued ATM usage given -$285M FCF and only $209M cash (roughly 9-month runway at current burn)
- · Manufacturing single-point-of-failure at Framingham — a cGMP compliance issue would halt supply with no CMO backup
- · FDA has already demonstrated willingness to reverse prior guidance and disregard a favorable AdCom vote (August 2025 sequence), so panel win is not sufficient
What to watch
- · Late July 2026 AdCom vote and briefing document tone — leading indicator into the PDUFA
- · August 2, 2026 PDUFA decision on RP1 + nivolumab BLA resubmission
- · August 6, 2026 earnings — cash position, ATM usage, and forward opex/runway commentary
- · Any 8-K on term loan covenants, additional ATM draws, or restructuring actions
- · Short interest trend into the AdCom — >50% of float would raise squeeze probability further
- · Key technical levels: 52-week high $12.50 as resistance, 52-week low $1.50 as downside reference on rejection
Key metrics
Price target rationale
Probability-weighted binary: bull case assumes RP1 approval, ~$1.5-2B EV on peak U.S. sales potential in ~10,400 patients plus pipeline optionality, implying ~$22 (near analyst high of $17 with squeeze overshoot); bear case is a third CRL forcing restructuring/wind-down with residual cash-and-pipeline value of ~$2.50 (analyst low $2); base case ~40% approval probability blends to ~$10, slightly below consensus given the two-CRL track record.
On Wall Street's view (mixed): The $12 consensus mean is roughly in line with the current $11.20 print and reasonably brackets a binary outcome given the $2 low and $17 high, but with only 6 analysts and a stock that just resolved one PDUFA negatively per the news, the average understates the bimodal payoff distribution.
Latest filing (10-K)
Replimune is a binary-event biotech whose entire near-term value rests on whether the FDA approves RP1 for anti-PD-1 failed melanoma by August 2, 2026 after two prior rejections, with management warning that failure could force a company restructuring.
Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies based on its proprietary RPx platform, which uses engineered HSV-1 viruses to selectively replicate in and kill tumor cells while stimulating systemic anti-tumor immune responses. The company has no approved products and generates no product revenue; it funds operations through equity offerings and a term loan facility. Its lead asset RP1 (vusolimogene oderparepvec) is under FDA BLA review for advanced melanoma in combination with Bristol Myers Squibb's nivolumab.
What the news says · neutral
REPL experienced an extraordinarily volatile week centered entirely on its FDA review of a melanoma treatment. The stock crashed ~32% on July 28 after negative FDA briefing documents, then surged as much as 127% after hours on July 31 following an 'overwhelmingly positive' AdCom vote, only to fall ~19% on August 1 when the FDA ultimately refused approval despite the favorable panel outcome. This whipsaw sequence — sell-off, massive rally, then rejection-driven decline — leaves the stock in a deeply uncertain position, with at least one analyst slashing their price target by 85%. The net result is a binary-event stock that has now seen its key catalyst resolve negatively, raising serious questions about the path to approval.
This analysis is from Aug 3, 2026. Markets move. Get the current read on REPL and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.